WO1996040620A1 - Retinoides de chalcone et leurs procedes d'utilisation - Google Patents
Retinoides de chalcone et leurs procedes d'utilisation Download PDFInfo
- Publication number
- WO1996040620A1 WO1996040620A1 PCT/US1996/011018 US9611018W WO9640620A1 WO 1996040620 A1 WO1996040620 A1 WO 1996040620A1 US 9611018 W US9611018 W US 9611018W WO 9640620 A1 WO9640620 A1 WO 9640620A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- compound
- chalcone
- cells
- retinoids
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 14
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 title abstract description 29
- 235000005513 chalcones Nutrition 0.000 title abstract description 29
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 title abstract description 11
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 39
- 201000011510 cancer Diseases 0.000 claims abstract description 34
- 150000001875 compounds Chemical class 0.000 claims description 56
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 230000001093 anti-cancer Effects 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000002955 immunomodulating agent Substances 0.000 claims description 3
- 229940121354 immunomodulator Drugs 0.000 claims description 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 230000002584 immunomodulator Effects 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000005907 alkyl ester group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 45
- -1 retinoid compounds Chemical class 0.000 abstract description 38
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 230000004071 biological effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 238000011282 treatment Methods 0.000 description 19
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 12
- 230000024245 cell differentiation Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- YEXOWHQZWLCHHD-UHFFFAOYSA-N 3,5-ditert-butyl-4-hydroxybenzoic acid Chemical compound CC(C)(C)C1=CC(C(O)=O)=CC(C(C)(C)C)=C1O YEXOWHQZWLCHHD-UHFFFAOYSA-N 0.000 description 8
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000007170 pathology Effects 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000118 anti-neoplastic effect Effects 0.000 description 6
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 6
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000011321 prophylaxis Methods 0.000 description 5
- 150000004492 retinoid derivatives Chemical class 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 208000005623 Carcinogenesis Diseases 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000036952 cancer formation Effects 0.000 description 4
- 231100000504 carcinogenesis Toxicity 0.000 description 4
- 150000001789 chalcones Chemical class 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 229930002330 retinoic acid Natural products 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- RKKNJQVSNIZPFI-UHFFFAOYSA-N 3,5-dibutyl-4-hydroxybenzoic acid Chemical compound CCCCC1=CC(C(O)=O)=CC(CCCC)=C1O RKKNJQVSNIZPFI-UHFFFAOYSA-N 0.000 description 3
- VTSRRUBZBLQJFB-UHFFFAOYSA-N 4-(3,5-ditert-butyl-4-hydroxybenzoyl)oxybenzoic acid Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C(=O)OC=2C=CC(=CC=2)C(O)=O)=C1 VTSRRUBZBLQJFB-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229960000956 coumarin Drugs 0.000 description 3
- 235000001671 coumarin Nutrition 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- ADVGKWPZRIDURE-UHFFFAOYSA-N 2'-Hydroxyacetanilide Chemical compound CC(=O)NC1=CC=CC=C1O ADVGKWPZRIDURE-UHFFFAOYSA-N 0.000 description 2
- SOUMNAXAAYKDPQ-UHFFFAOYSA-N 4-[(3,5-ditert-butyl-4-hydroxybenzoyl)amino]benzoic acid Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C(=O)NC=2C=CC(=CC=2)C(O)=O)=C1 SOUMNAXAAYKDPQ-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 208000006994 Precancerous Conditions Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- WUADCCWRTIWANL-UHFFFAOYSA-N biochanin A Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O WUADCCWRTIWANL-UHFFFAOYSA-N 0.000 description 2
- 230000002113 chemopreventative effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940117173 croton oil Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000004452 microanalysis Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940100552 retinamide Drugs 0.000 description 2
- 125000001444 retinoyl group Chemical group O=C([*])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- HVAWOUBDYOECOJ-UHFFFAOYSA-N (4-acetamidophenyl) 4-[3-(3,5-ditert-butyl-4-methoxyphenyl)-3-oxoprop-1-enyl]benzoate Chemical compound C1=C(C(C)(C)C)C(OC)=C(C(C)(C)C)C=C1C(=O)C=CC1=CC=C(C(=O)OC=2C=CC(NC(C)=O)=CC=2)C=C1 HVAWOUBDYOECOJ-UHFFFAOYSA-N 0.000 description 1
- GVSPXQVUXHMUMA-MDWZMJQESA-N (e)-3-(3,5-ditert-butyl-4-hydroxyphenyl)-1-(4-methoxyphenyl)prop-2-en-1-one Chemical compound C1=CC(OC)=CC=C1C(=O)\C=C\C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 GVSPXQVUXHMUMA-MDWZMJQESA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 1
- CPTVTYJFEKOZDW-UHFFFAOYSA-N 4-[(3,5-ditert-butyl-4-methoxybenzoyl)amino]benzoic acid Chemical compound C1=C(C(C)(C)C)C(OC)=C(C(C)(C)C)C=C1C(=O)NC1=CC=C(C(O)=O)C=C1 CPTVTYJFEKOZDW-UHFFFAOYSA-N 0.000 description 1
- MTKVDTKTZDMDFC-UHFFFAOYSA-N 4-[4-(2-acetamidophenoxy)carbonylphenyl]-3,5-ditert-butyl-4-hydroxycyclohexa-1,5-diene-1-carboxylic acid Chemical compound CC(=O)NC1=CC=CC=C1OC(=O)C2=CC=C(C=C2)C3(C(C=C(C=C3C(C)(C)C)C(=O)O)C(C)(C)C)O MTKVDTKTZDMDFC-UHFFFAOYSA-N 0.000 description 1
- OZBUFFXESDBEHG-FXILSDISSA-N 4-[[(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoyl]amino]benzoic acid Chemical compound C=1C=C(C(O)=O)C=CC=1NC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OZBUFFXESDBEHG-FXILSDISSA-N 0.000 description 1
- FZYOVDIUQFXUDM-UHFFFAOYSA-N 4-[[4-(3,5-ditert-butyl-4-hydroxybenzoyl)oxybenzoyl]amino]benzoic acid Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C(=O)OC=2C=CC(=CC=2)C(=O)NC=2C=CC(=CC=2)C(O)=O)=C1 FZYOVDIUQFXUDM-UHFFFAOYSA-N 0.000 description 1
- CAJBWAOIUBOQHI-UHFFFAOYSA-N 4-[[4-[3-(3,5-ditert-butyl-4-methoxyphenyl)-3-oxoprop-1-enyl]benzoyl]amino]benzoic acid Chemical compound C1=C(C(C)(C)C)C(OC)=C(C(C)(C)C)C=C1C(=O)C=CC1=CC=C(C(=O)NC=2C=CC(=CC=2)C(O)=O)C=C1 CAJBWAOIUBOQHI-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 241000766026 Coregonus nasus Species 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 101000573199 Homo sapiens Protein PML Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229940121849 Mitotic inhibitor Drugs 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000004179 Oral Leukoplakia Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 241000219781 Pueraria montana var. lobata Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047760 Vulval leukoplakia Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010817 Wright-Giemsa staining Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000001621 anti-mitogenic effect Effects 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000008375 benzopyrones Chemical class 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- AJSDVNKVGFVAQU-BIIVOSGPSA-N cladinose Chemical compound O=CC[C@@](C)(OC)[C@@H](O)[C@H](C)O AJSDVNKVGFVAQU-BIIVOSGPSA-N 0.000 description 1
- 231100000313 clinical toxicology Toxicity 0.000 description 1
- 238000009643 clonogenic assay Methods 0.000 description 1
- 231100000096 clonogenic assay Toxicity 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000003134 dye exclusion method Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
- 229960002199 etretinate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 102000054896 human PML Human genes 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002700 inhibitory effect on cancer Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003887 myelocyte Anatomy 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 230000027498 negative regulation of mitosis Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 201000008557 oral mucosa leukoplakia Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- PWXJULSLLONQHY-UHFFFAOYSA-N phenylcarbamic acid Chemical class OC(=O)NC1=CC=CC=C1 PWXJULSLLONQHY-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000004508 retinoic acid derivatives Chemical class 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000462 teratogen Toxicity 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 239000003439 teratogenic agent Substances 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
Definitions
- the present invention relates to novel retinoids, as chalcone retinoids, and compositions thereof, which exhibit therapeutic and/or biological activity on cancer or precancer cells, as well as to methods of using same.
- Retinoids play an important role in the development and differentiation of epidermal cells, as well as in reversing precancerous lesions.
- Clinical trials have been conducted using N- (4-carboxyphenyl) retinamide in the treatment of some precancerous lesions, oral leukoplakia, vulval leukoplakia, atypical dysplasia of the cervix and the gastric mucosa, and the like (Han et al. , in vivo 4,:153-160 (1990)) .
- Other retinoids, such as isoretinoin and etretinate are in current use as prescription drugs for the treatment of acne and psoriasis (Gander et al. , U.S. Patent No. 4,126,693) .
- retinoids have a significant level of toxicity, and treatment using known retinoid agents suffers from problems due to the level of toxicity and side effects which accompany administration of known retinoid compounds. Accordingly, there exists a need to provide novel compounds having retinoid activity but which have less toxicity and/or side effects.
- Smith et al. J. Clin . Oncol . _J_ (5) :839-864 (1992), reviews the use of retinoids in cancer therapy with most of the emphasis on anti-tumor effects in patients with acute promyelocytic leukemia (APL) .
- Smith et al. reports that the natural retinoid, all-trans-retinoic acid (RA) ,
- AML acute myeloid leukemia
- neuroblastoma neuroblastoma
- teratqcarcino a neuroblastoma
- melanoma teratqcarcino a
- rat rhabdomyosarcoma rat rhabdomyosarcoma cells
- Clinical toxicities associated with the use of RA in dermatologic studies are listed in Table 6 of the Smith et al . reference with disclosure in the text that retinoids are recognized as powerful teratogens.
- 1,127,170 is specifically directed to retinic acid N- (carboxy) -phenylamindes and 7, 8-dehydro-retinic acid N- (carboxy) -phenylamides, and discloses that, while the retinic compounds are predominantly directed toward preventing cancer, they may be used for therapeutic treatment of tumors of the bladder, the mammary gland, the skin and the mucous membranes.
- a number of references disclose retinoids being used in cancer prophylaxis and as inducers of cell differentiation. For instance, Newton et al. , Cancer Res . 4.0:3413-3425 (1980) discloses a long list of esters, amines and amides of retinoic acid and their activity in cancer prophylaxis.
- Preuss-Ueberschar et al. Drug Res . 3_4:1305-1313 (1984) discloses that benzopyrones, which include coumarin, are not teratogenic.
- the pharmacology of coumarir.-related compounds is reviewed by Egan et al . which indicates that coumarin-related compounds are known to inhibit the carcinogenicity of carcinogens and that coumarin has been tested for treatment of melanoma.
- Another object of the present invention is to provide novel retinoids, as chalcone retinoids, which have anti-neoplastic activity in vi tro .
- a further object of the present invention is to provide novel retinoids, as chalcone retinoids, which have anti-neoplastic activity in vivo .
- a still further object of the present invention is to provide novel retinoid compounds and compositions, using methods of the present invention, which compounds and/or compositions are useful for research and/or pharmaceutical applications in mammals, particularly humans.
- retinoid compounds and compositions synergistically combine the cell differentiation activity of retinoids with the mitotic inhibitor activity of chalcones.
- retinoids are also useful as chemotherapeutic agents in vitro, in si tu and/or in vivo.
- Yet another object of the present invention is to provide synthetic methods for obtaining retinoid compounds and/or compositions according to formula (I) as descriptively enabled herein.
- the invention is also directed to a method for treating a subject having a precancer or a cancer- related pathology by administering at least one retinoid compound and/or composition comprising or consisting essentially of a chalcone retinoid, optionally further comprising or consisting essentially of at least one anti-cancer pharmaceutical and/or immunomodulator.
- the present invention provides a new and biologically active group of retinoids which display cancer chemoprevention activity.
- retinoids which display cancer chemoprevention activity.
- These derivatives include, but are not limited to, compounds according to the following formula (I) as chalcone retinoids.
- the chalcone retinoids in accordance with the present invention have the following formula (I) :
- R ! OH or C ⁇ -C 5 alkoxy
- R 2 OH, carboxy, C,-C 6 alkyl ester, or NHCOR 3 where R 3 is methyl, ethyl, propyl or butyl
- X NH or C 2 -C 4 alkenyl
- Z NH or 0.
- R 2 is preferably selected from the group consisting of OH, COOC 2 H 5 C00C 3 H 7 , COOCH 3 , COOH, NHCOCH j , NHCOCH 2 CH 3 .
- the following compounds (I-A) - (I-S) shown in Table 1 are non-limiting examples of compounds according to formula (I) , and such compounds in any combination are provided as compounds or compositions according to the present invention:
- Such retinoids of the present invention are unexpectedly discovered to have anti-cancer activity, thus providing suitable compounds and compositions for treatment of cancer-related pathologies, optionally with additional pharmaceutically active ingredients, such as antiviral, chemotherapeutic agents and/or immuno-stimulating compounds, or antiviral antibodies or fragments thereof, in vi tro, in si tu, and/or in vivo.
- additional pharmaceutically active ingredients such as antiviral, chemotherapeutic agents and/or immuno-stimulating compounds, or antiviral antibodies or fragments thereof, in vi tro, in si tu, and/or in vivo.
- Cancer-related pathologies in the context of the present invention include, but are not limited to, tumors and pathologies involving tumorigenesis, leukemias, lymphomas, melanomas, sarcomas, virus-related cancers, and any other known cancers.
- anti-cancer activity is intended to mean the ability to induce at least one of (1) inhibition of growth or mitosis of transformed, mutated, preneoplastic or neoplastic cells; (2) promotion of apoptosis; and/or (3) angiogenesis inhibition.
- inhibition or stimulation is between 10 and 100 percent inhibition and 10 and 1000 percent stimulation, relative to a suitable control, such as, but not limited to the same cell or animal under the same conditions, except for the presence or administration of one or more retinoids according to the present invention.
- the present invention also provides synthetic methods for obtaining retinoid compounds according to formula (I) , which would be clear to one of ordinary skill in the art, based on the teaching and guidance presented herein, in combination with what is known in the related fields of art.
- components of completely synthesized chalcone compounds and/or retinoyl compounds can be provided as starting materials, and the appropriate side groups can be added, modified or used in suitable, known chemical reaction steps to provide retinoid compounds according to formula (I) .
- a solution of a specific molar amount (e.g., 2.5 mmole) of a chalcone derivative is provided in a suitable amount (e.g., 20 ml) of an anhydrous organic solvent (e.g., anhydrous tetrahydrofuran (THF) ) , and a slight excess (e.g., 2.75 mmole) of a secondary or tertiary alkyl substituted amine (e.g., triethylamine) is added.
- anhydrous organic solvent e.g., anhydrous tetrahydrofuran (THF)
- THF anhydrous tetrahydrofuran
- an excess molar amount (e.g., 2.75 mmole) of an alkyl halo formate (e.g., ethyl chloroformate) is added dropwise and stirred at room temperature for 0.2-3.0 hours (e.g., 1 hr.) .
- Petroleum ether is then added and the separated solid filtered.
- the filtrate is then concentrated in vacuo to dryness.
- a suitable amount of anhydrous organic solvent e.g., 20 ml of anhydrous acetonitrile
- an alkyl substituted phenol e.g., 2.5 mmole of acetaminophenol
- the mixture is then warmed to a clear solution and a suitable amount (e.g., 0.25 g) of the secondary or tertiary alkyl substituted amine (e.g., triethylamine) and another suitable amount (e.g., 20 mg) of a disubstituted alkyl amino pyridine (e.g., 4-dimethylaminopyridine) is added while stirring.
- a suitable amount e.g. 0.25 g
- the secondary or tertiary alkyl substituted amine e.g., triethylamine
- a disubstituted alkyl amino pyridine e.g., 4-dimethylaminopyridine
- the mixture is heated to 40-60 ° C (e.g., 50°C) for 0.5-3 hours (e.g., 1 hr.) to concentrate the mixture to half its original volume by solvent removal. Crystals formed from the concentration of the mixture are collected, washed, and recrystall
- vi tro assays for determining whether a given compound and/or composition has anti ⁇ neoplastic activity. Such methods are well known in the art and provide the means for one of ordinary skill in the art to determine, using routine experimentation, whether a given retinoid of the present invention has a specific anti-cancer activity for a given cancer-related pathology. The following are examples of methods which can be used to screen chalcone retinoids according to formula (I) for determining at least one pharmaceutical utility; without undue experimentation, based on the teaching and guidance presented herein.
- Non-limiting examples of anti-neoplastic in vi tro activity include but are not limited to, activity (1) against phosphorylation of phospholipids promoted by tetradecanoylphorbol-13-acetate in HeLa cells as a screening test for anti-tumor promoting effect; (see, e.g., Shibata,
- Non-limiting examples of anti-neoplastic in vivo activity include, but are not limited to, activity in (1) inhibition of tumorigenesis in mouse skin tumors (see, e.g., Shibata, Stem Cells 12:44-52 (1994)) ; (2) inhibition of animal carcinogenesis model systems (see, e.g., Kennedy, Prev. Med.
- predictive statistics and artificial intelligence can be used to provide computer programs which integrate matrix data to calculate patterns of activity, structural motifs, and a cell's expression of molecular targets to predict a given compound's mechanism of action to combine screening assay data and structure based drug design and testing, einstein et al. , Stem Cells 12:12-22 (1994), the contents of which reference is entirely incorporated herein by reference.
- compositions comprising chalcone retinoid compounds of the present invention, include all compositions wherein at least one pharmaceutical compound or composition is contained in an amount effective to achieve its intended purpose.
- pharmaceutical compositions containing at least one pharmaceutical compound or composition may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
- Pharmaceutical compositions of the present invention can also include anti-neoplasties and/or immunomodulators.
- a pharmaceutical compound or composition of the present invention may further comprise or consist essentially of at least one member selected from a single chain ribosome inhibitory protein (acting to block expression of a cancer related protein in a cancer related receptor cell or tissue) ; a cytokine; or a growth factor.
- Cytokines that are produced by lymphocytes are termed lymphokines, whereas peptides produced by monocytes or macrophages are given the term monokines .
- the terms cytokines, lymphokines, and interleukins may be used interchangeably to designate those peptide molecules that modulate host responses to foreign antigens or host injury by regulating the growth, mobility and differentiation of leukocytes and other cells .
- Cytokines used according to the present invention are those suitable for use as additional active ingredients of compositions of the present invention.
- a cytotoxic or a chemotherapeutic agent may be further included in a pharmaceutical composition of the present invention, optionally further comprising a delivery vector that preferentially binds to, or facilitates association of the pharmaceutical/diagnostic compound or composition with pathologic cells as target cells involved in cancer.
- the targets for this type of therapy can also be growth factor receptors, differentiation antigens, or other less characterized cell surface antigens specifically associated with cancer or precancer cells.
- Pharmaceutical compositions can also include suitable solutions for administration by injection or orally, and contain from about 0.001 to 99 percent, preferably from about 20 to 75 percent of active component.
- Pharmaceutical compositions for oral administration include tablets and capsules. Compositions which can be administered rectally include suppositories.
- Non- sprayable forms can be semi-solid or solid forms comprising a carrier conducive to topical application and having a dynamic viscosity preferably greater than that of water.
- sprayable aerosol preparations where the active ingredient is preferably in combination with a solid or liquid inert carrier material.
- the aerosol preparations can contain solvents, buffers, surfactants, perfumes, and/or antioxidants in addition to the retinoid compounds or compositions of the present invention.
- compositions of the present invention may be administered by any means that achieve its intended purpose, for example, to treat or prevent a cancer or precancerous condition.
- protection as in “protection from a cancerous or precancerous condition”, as used herein, encompasses “prevention,” “suppression” or “treatment.”
- prevention involves administration of a pharmaceutical composition prior to the induction of the disease.
- “Suppression” involves administration of the composition prior to the clinical appearance of the disease. “Treatment” involves administration of the protective composition after the appearance of the disease. It will be understood that in human and veterinary medicine, it is not always possible to distinguish between “preventing” and “suppressing” since the ultimate inductive event or events may be unknown, latent, or not ascertained in the patient until well after the occurrence of the event or events. Therefore, it is common to use the term ' “prophylaxis” as distinct from “treatment” to encompass both “preventing” and “suppressing” as defined herein.
- the term “protection, " as used herein, is meant to include “prophylaxis.” See, e.g., Berkow et al, eds.
- At least one retinoid compound or composition of the present invention may be administered by any means that achieves the intended purpose, using a pharmaceutical composition as previously described.
- administration may be by various parenteral routes such as subcutaneous, intravenous, intradermal, intramuscular, intraperitoneal, intranasal, intracranial, transdermal, or buccal routes.
- Parenteral administration can also be by bolus injection or by gradual perfusion over time.
- administration may be by the oral route.
- An additional mode of using of a pharmaceutical compound or composition of the present invention is by topical application.
- a pharmaceutical compound or composition of the present invention may be incorporated into topically applied vehicles such as salves or ointments.
- a typical regimen for treatment or prophylaxis includes administration of an effective amount over a period of one or several days, up to and including between one week and about six months.
- the dosage of a pharmaceutical compound or composition of the present invention administered in vivo will be dependent upon the age, sex, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the pharmaceutical effect desired.
- the ranges of effective doses provided herein are not intended to be limiting and represent preferred dose ranges. However, the most preferred dosage will be tailored to the individual subject, as is understood and determinable by one skilled in the relevant arts.
- the total dose required for each treatment may be administered by multiple doses or in a single dose.
- the pharmaceutical compound or composition may be administered alone or in conjunction with other pharmaceuticals directed to the pathology, or directed to other symptoms of the pathology.
- Effective amounts of a pharmaceutical compound or composition of the present invention are from about 0.001 ⁇ g to about 100 mg/kg body weight, preferably about 5 mg/kg to 100 mg/kg body weight, most preferably about 20 mg/kg to 50 mg/kg body weight administered at intervals of 4-72 hours, for a period of 2 days to 5 years.
- the compounds and/or compositions of the present invention are to be administered to preferably mammalian recipients, most preferably humans. Having now generally described the invention, the same will be more readily understood through reference to the following example which is provided by way of illustration, and is not intended to be limiting of the present invention.
- Example 1 A Chalcone Retinoid Compound (I-N) According to Formula I
- the purified retinoyl compound-chalcone derivative was crystallized from dilute alcohol, with a yield of 0.4 g (51.3%), and the following characteristics: mp:306-- 308°C, and MS (m/z) 513 (M + ) , 498, 377(100%) , 349, 319.
- Example 8 A Chalcone Retinoid Compound (I-S) According to Formula I
- Human promyelocytic leukemia HL-60 cells were cultured in RPMI-1640 medium supplemented by 10% heat- inactivated calf serum and 100 U/ml of penicillin plus 100 ⁇ g/ml of streptomycin. The flasks containing cells and medium were incubated in an incubator with 5% C0 2 at 37°C. Log phase cells were seeded into the medium at a concentration of 1.2xl0 5 to 1.4xl0 5 cells per ml and cultured in flasks containing 5 ml of medium. Each group consisted of three flasks. Different concentrations of chalcone-retinoids were added.
- NBT reducing activity For a determination of NBT reducing activity, a . portion of the chalcone-retinoid-treated cells was removed at intervals following treatment and centrifuged. After centrifugation, 0.5 ml of 0.1% NBT (containing 100 ng TPA) was added to each tube. The contents of the test tubes were then incubated for 1 hour at 37°C. Cell smears were prepared from the cell sediment and stained using the Wrigh -Giemsa technique. For each smear prepared, 200 cells were isolated for examination under a light microscope with an oil immersion lens. Cells stained with blue-black granules were considered NBT-positive cells. The 50% differentiation or effective concentration (ED 50 or EC 50 ) is shown in terms of molar (M) concentration of the coumarin-retinoid tested.
- M molar
- a cell smear was prepared at intervals following treatment of cells for each chalcone-retinoid concentration group using the Wright- Giemsa stain technique. Stained cells were counted and classified under a light microscope with an oil immersion lens. After treatment with coumarin-retinoids, the morphological development of HL-60 cells proceeded toward mature granulocytes. This development was manifested by decreased cell volume; a lower nuclei to cytoplasm ratio; smaller or missing nuclei; concentration of chromatin; and the appearance of a certain proportion of intermediate and late granuloblasts (progranulocytes) , elongated rod granulocytes, and granulocytes with branched nuclei.
- progranulocytes intermediate and late granuloblasts
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96922607A EP0832060A1 (fr) | 1995-06-07 | 1996-06-07 | Retinoides de chalcone et leurs procedes d'utilisation |
NZ311995A NZ311995A (en) | 1995-06-07 | 1996-06-07 | Chalcone retinoids and methods of use of same in cancer and precancer cells |
JP9502320A JPH11511121A (ja) | 1995-06-07 | 1996-06-07 | カルコンレチノイドおよびその使用方法 |
IL12234196A IL122341A0 (en) | 1995-06-07 | 1996-06-07 | Retinoid derivatives and their use |
AU63423/96A AU702423B2 (en) | 1995-06-07 | 1996-06-07 | Chalcone retinoids and methods of use of same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47557395A | 1995-06-07 | 1995-06-07 | |
US08/475,573 | 1995-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996040620A1 true WO1996040620A1 (fr) | 1996-12-19 |
Family
ID=23888175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/011018 WO1996040620A1 (fr) | 1995-06-07 | 1996-06-07 | Retinoides de chalcone et leurs procedes d'utilisation |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0832060A1 (fr) |
JP (1) | JPH11511121A (fr) |
AU (1) | AU702423B2 (fr) |
CA (1) | CA2223948A1 (fr) |
IL (1) | IL122341A0 (fr) |
NZ (1) | NZ311995A (fr) |
WO (1) | WO1996040620A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8188277B2 (en) | 2004-08-06 | 2012-05-29 | Otsuka Pharmaceutical Co., Ltd. | Aromatic compounds for suppressing the generation of collagen |
US8236826B2 (en) | 2005-12-05 | 2012-08-07 | Otsuka Pharmaceutical Co., Ltd. | Diarylether derivatives as antitumor agents |
US8263599B2 (en) | 2006-10-02 | 2012-09-11 | Otsuka Pharmaceutical Co., Ltd. | STAT3/5 activation inhibitor |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0404039A1 (fr) * | 1989-06-23 | 1990-12-27 | Roche Diagnostics GmbH | Médicaments contenant des dérivés di-tert.butylhydroxyphényliques et dérivés |
WO1993023357A1 (fr) * | 1992-05-21 | 1993-11-25 | Research Corporation Technologies, Inc. | Derives de stilbene utilises comme agents anticancereux |
JPH06247919A (ja) * | 1992-12-28 | 1994-09-06 | Medicine Inst Chinese Acad Medical Science | 安息香酸誘導体およびその用途 |
-
1996
- 1996-06-07 JP JP9502320A patent/JPH11511121A/ja active Pending
- 1996-06-07 AU AU63423/96A patent/AU702423B2/en not_active Ceased
- 1996-06-07 EP EP96922607A patent/EP0832060A1/fr not_active Ceased
- 1996-06-07 NZ NZ311995A patent/NZ311995A/xx unknown
- 1996-06-07 IL IL12234196A patent/IL122341A0/xx unknown
- 1996-06-07 WO PCT/US1996/011018 patent/WO1996040620A1/fr not_active Application Discontinuation
- 1996-06-07 CA CA002223948A patent/CA2223948A1/fr not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0404039A1 (fr) * | 1989-06-23 | 1990-12-27 | Roche Diagnostics GmbH | Médicaments contenant des dérivés di-tert.butylhydroxyphényliques et dérivés |
WO1993023357A1 (fr) * | 1992-05-21 | 1993-11-25 | Research Corporation Technologies, Inc. | Derives de stilbene utilises comme agents anticancereux |
JPH06247919A (ja) * | 1992-12-28 | 1994-09-06 | Medicine Inst Chinese Acad Medical Science | 安息香酸誘導体およびその用途 |
Non-Patent Citations (1)
Title |
---|
CHEMICAL ABSTRACTS, vol. 122, no. 13, 27 March 1995, Columbus, Ohio, US; abstract no. 151372m, KAKU S.: "Benzoates and IgE formation inhibitors containing them" page 151380; XP002015619 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8188277B2 (en) | 2004-08-06 | 2012-05-29 | Otsuka Pharmaceutical Co., Ltd. | Aromatic compounds for suppressing the generation of collagen |
US8236826B2 (en) | 2005-12-05 | 2012-08-07 | Otsuka Pharmaceutical Co., Ltd. | Diarylether derivatives as antitumor agents |
US8263599B2 (en) | 2006-10-02 | 2012-09-11 | Otsuka Pharmaceutical Co., Ltd. | STAT3/5 activation inhibitor |
Also Published As
Publication number | Publication date |
---|---|
AU6342396A (en) | 1996-12-30 |
CA2223948A1 (fr) | 1996-12-19 |
NZ311995A (en) | 1999-03-29 |
MX9709982A (es) | 1998-06-28 |
JPH11511121A (ja) | 1999-09-28 |
IL122341A0 (en) | 1998-04-05 |
EP0832060A1 (fr) | 1998-04-01 |
AU702423B2 (en) | 1999-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4703110A (en) | Benzoic acid derivatives having a para substituent which is a substituted phenyl group connected by a linking radical; useful in neoplastic cell differentiation and diagnosis | |
US6534544B1 (en) | Methods of treatment with compounds having RARα receptor specific or selective activity | |
RU2197477C2 (ru) | Производные адамантана, способ их получения, фармацевтическая композиция на их основе, способ ее получения и способ воздействия на иммуносупрессию | |
EP1268405B1 (fr) | Traitement de tumeurs avec des composes retinoides selectifs de rar alpha en combinaison avec d'autres agents antitumoraux | |
EP1720825B1 (fr) | Derives de l'acide anthranilique, procedes destines a leur preparation et utilisation comme inhibiteurs de dhodh | |
US5475130A (en) | Anilide derivative | |
EP0799188B1 (fr) | Amides d'acides mono et bicarboxyliques a glycosamines, a activite selective sur le recepteur peripherique des cannabinoides | |
WO1996007652A1 (fr) | Mimetiques de la calicheamicine | |
CN102702052B (zh) | 含有二胺类的新型法尼基硫代水杨酸衍生物、其制备方法及其医药用途 | |
Wei et al. | Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer | |
US5703130A (en) | Chalcone retinoids and methods of use of same | |
US5716982A (en) | Retinoids and methods of use of same | |
JP2010521421A (ja) | アポトーシスを誘導するイミダゾール誘導体とその治療的用途 | |
KR0135723B1 (ko) | 신규한 에스큘레틴 유도체 및 약학 조성물 | |
AU702423B2 (en) | Chalcone retinoids and methods of use of same | |
Xu et al. | Discovery of 1, 2-diphenylethene derivatives as human DNA topoisomerase II catalytic inhibitors and antitumor agents | |
US5968940A (en) | Retinoids and methods of use of same | |
CA2178479C (fr) | Derive de chromanne | |
WO2010093615A2 (fr) | Composés, leurs synthèses, leurs compositions et méthodes pour traiter le cancer | |
MXPA97009982A (en) | Retinoids of chalcona and use of mis | |
Xu et al. | Structure-activity relationship studies on O-alkylamino-tethered salicylamide derivatives with various amino acid linkers as potent anticancer agents | |
JP2008542202A (ja) | N−(4−ヒドロキシベンジル)レチノンのc−連結されたグルコロニド、それの類似体、並びに新生物性の細胞の成長を阻害するためにそれを使用する方法 | |
Lien et al. | Effect of Indole‐3‐Acetic Acid Analogs on the Differentiation of HL‐60 Cells | |
MXPA97009979A (en) | Retinoids and methods of using the mis | |
Jovanović | Review of the article „Synthesis and Evaluation of Novel Chromanone and Quinolinone Analogues of Uniflorol as Anti-Leishmanial Agents “, verified by Publons, Web of Science |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96194473.0 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2223948 Country of ref document: CA Ref document number: 2223948 Country of ref document: CA Kind code of ref document: A Ref document number: 1997 502320 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/009982 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996922607 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 311995 Country of ref document: NZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1996922607 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWR | Wipo information: refused in national office |
Ref document number: 1996922607 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996922607 Country of ref document: EP |